Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma
Brief Summary: This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)


Options:
A: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)
B: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab, Procedure: Surgery, Radiation: IMRT | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab, Procedure: Surgery, Radiation: IMRT, Drug: Lenvatinib | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: RADIATION; Name: IMRT; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Cohort B
C: Arm Label: Arm A (nivolumab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm B (nivolumab, ipilimumab, surgery); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm C (nivolumab, relatlimab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Biological: Relatlimab, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B (nivolumab, ipilimumab, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Relatlimab; Assigned to Arm(s): Arm C (nivolumab, relatlimab, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery)
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: temozolomide | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: CP-675,206 | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: CP-675,206; Assigned to Arm(s): A | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): B

Answer: D